

| | INVICTA DIAGNOSTIC LIMITED INITIAL PUBLIC OFFER - NR | | | | | | | | | | Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent | | | | | | | | | | Bid cum Application Form No. | | | | | | | | | | | | | | | | | | | |
|--|---|---|----------|----------|----------|----------|----------|----------|----------------------|--------------------------|--|--|---------------|--|--|--|-------------------------------|--|--|----------------------------------|--|--|--|--|--|--|--|--|--|--|---|--|--|--|--|--|--|--|--|--|
| | PD ID / CL ID | | | | | | | | | | PAN of Sole / First Bidder | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Amount blocked (₹ in figures) | | | | | | | | | | ASBA Bank A/c No./UPI ID | | | | | | | | | | Stamp & Signature of SCSB Branch | | | | | | | | | | | | | | | | | | | | |
| Bank Name & Branch | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Received from Mr./Ms./M/s. _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Telephone / Mobile | | | | | | | | | | Email | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TEAR HERE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| INVICTA DIAGNOSTIC LIMITED-INITIAL PUBLIC OFFER-NR | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;"></th> <th style="width: 25%;">Option 1</th> <th style="width: 25%;">Option 2</th> <th style="width: 25%;">Option 3</th> </tr> <tr> <td>No. of Equity Shares</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Bid Price (₹)</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="4" style="padding: 5px;"> Amount Blocked (₹ in figures) </td> </tr> </table> | | | | Option 1 | Option 2 | Option 3 | No. of Equity Shares | | | | Bid Price (₹) | | | | Amount Blocked (₹ in figures) | | | | Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent | | | | | | | | | | Name of Sole / First Bidder _____ _____ | | | | | | | | | |
| | | | Option 1 | Option 2 | Option 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | No. of Equity Shares | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Bid Price (₹) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Amount Blocked (₹ in figures) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ASBA Bank A/c No./UPI ID _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Bank Name & Branch _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| INVICTA DIAGNOSTIC LIMITED-INITIAL PUBLIC OFFER-NR | | Acknowledgement Slip for Bidder | | | | | | | | | | Bid cum Application Form No. | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | INVICTA DIAGNOSTIC LIMITED | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS
DATED NOVEMBER 24, 2025 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE ISSUE OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the RHP dated November 24, 2025, filed with the Registrar of Companies, Mumbai, Maharashtra, the General Information Document for Investing in Public Issue ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Issue upto my/our Bids for maximum number of Equity Shares at or above the Issue Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible person(s) to invest in the Issue in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSB or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP, Abridged Prospectus, the GID, the Bid cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders, only the SCSBs (for Bids other than the Bids by Anchor Investors), and the BRLM and their affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP. I/we authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Issue. I/we confirm that I/we have read the RHP. My / our investment decision is solely based on the RHP and the Prospectus.

I/WE CONFIRM THAT: either I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity shares as nominees of any person resident outside India or foreign nationals or I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity shares on my/our own behalf through NRO account on non-repatriation basis. I/we represent, warrant, acknowledge and agree with the Company and the BRLM as follows: (A) I/we have read the RHP and that my/our investment decision is based solely on the RHP. (B) I/we have read and agree to the representations, warranties and agreements contained in the section "Other Regulatory and Statutory Disclosures/Disclaimer in respect of Jurisdiction" in the RHP. (C) The Equity Shares offered in this Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws and that the Equity Shares are being offered and sold only outside the United States in accordance with Regulation S under the Securities Act. (D) I was/we were outside of the United States at the time the issue of the Equity Shares was made to me/us and I am/we are outside the United States at the time I/we signed this Bid cum Application Form; (E) the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction; (F) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (G) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (H) if I/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (I) if I/we are making an application to acquire any of the Equity shares for one or more managed accounts, I am / we are authorized in writing by each such managed account to subscribe to the Equity shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: (1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI/CDR Regulations") and as disclosed in the RHP, I/we authorise (a) the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or the RTAs (at the Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Issue, including uploading our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSB as specified in the Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid cum Application Form, as the case may be, transfer of funds to the Public Issue Account on receipt of instruction from Registrar to the Issue or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Issue or Sponsor Bank, as the case may be, to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. (2) In the case amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB/Registrar to the Issue shall reject the application. (3) I/we hereby authorise the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide our consent to the Stock Exchanges / Sponsor Bank / NPCI / Registrar to the Issue for collecting, storing and usage validating our PAN details from the bank account where my / our amount is blocked by the relevant SCSBs.

I/we acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Issue. I am/We are not an OCB. For further details, see "Issue Procedure" and "Restriction on Foreign Ownership of Indian Securities" beginning on page 311 and 330, respectively of the RHP.

INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM

- Name of sole/First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an 'indication to make an Issue' during the Bid/Issue period by a Bidder and not 'an Issue'.
- The First Bidder, should mention his/her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Issue will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment and delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Issue nor RTAs/CDPs nor the SCSBs nor the Company shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The Price Band and the minimum Bid Lot has been decided by our Company in consultation with the Book Running Lead Manager. Price Band is ₹ 80/- to ₹ 85/- per Equity Share. The floor price is 8.00 times of the face value and the cap price is 8.50 times of the face value. Minimum Bid Lot is 3200 Equity Shares and in multiples of 1600 Equity Shares thereafter. The Bid/Issue period shall be for a minimum of 3 Working Days and shall not exceed 10 Working Days. In case of revision of the Price Band the Bid/Issue Period will be extended for at least three additional working days subject to the total Bid/Issue Period not exceeding 10 working days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release and also by indicating the changes on the websites of the BRLM and on the terminals of the Syndicate Members.
- Maximum and Minimum Bid Size:** In case of Individual Bidders, 2 lots such that the Bid size shall be above ₹2.00 lakhs. In case of QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹2.00 lakhs. For Non-Institutional Bidder's applying under one-third of the Non-Institutional Portion, the minimum bid size (with bid size of more than two lots and up to such lots equivalent to not more than ₹10.00 lakhs) shall be of such number of Equity Shares in multiples of the minimum bids, such that that the Bid size exceeds two lots. For NIBs applying under two thirds of the Non-Institutional Portion (with bid size of more than ₹10.00 lakhs) such number of Equity Shares in multiples of Equity Shares, such that the Bid Amount exceeds ₹10.00 lakhs. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSB to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered and Corporate Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centers. In accordance with applicable law and SEBI UPI Circulars, Bidders to please ensure that SCSB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. UPI Bidders applying up to ₹5.00 lakhs shall apply through UPI mode as per NPCI vide circular reference no. NPCI/UIP/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI ICDR Master Circular.
 - UPI Bidders using UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public Issue.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 311 of the RHP.
- Only the First Bidder is required to sign the Bid cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021. You may send the RHP and the Prospectus either in physical form or electronic form or both. You shall not distribute or forward this documents and these documents are subject to the disclaimers and restrictions contained in or accompanying in it.
- The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur.
- This Bid cum Application Form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgement set out in "Other Regulatory and Statutory Disclosures" and "Issue Procedure" on pages 289 and 311 respectively of the RHP and (ii) agree to abide by (1) this Bid cum Application Form and (2) the RHP together with the terms and conditions contained therein.

Note : Terms used but not defined herein shall have the meaning assigned to such terms in the RHP. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLM and the Stock Exchanges.


TEAR HERE

- In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Issue.
- In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB.
- In case of queries related to upload of Bids submitted to the relevant Members of the Syndicate / RTAs Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary.
- For UPI related queries, investors can contact NPCI at the toll free number- 18001201740 and Mail Id- ipo.upi@npci.org.in and the Registrar to the Issue at Tel: 022 - 6263 8200 and E-mail: ipo@bigshareonline.com
- In case of ASBA Bidders (other than 3-in-1 Bids) for a bid above INR 5,00,000, ensure that the bid is uploaded only by the SCSBs
- Ensure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 5:00 p.m. of the Bid/ Issue Closing Date

COMPANY CONTACT DETAILS
INVICTA DIAGNOSTIC LIMITED
Registered Office: 1 GF, Plot 217, Ambavat Bhavan, N.M.Joshi Marg, Delisle Road, Mumbai - 400 013, Maharashtra, India;
Corporate Office: Office No. 1012, 10th Floor, Hubtown Viva CHS Ltd, Western Express Highway, Mogra Village, Near Shankar Wadi, Jogeshwari East, Mumbai - 400 060, Maharashtra, India;
Telephone: 022 - 4971 0036;
Contact Person: Soniya Nilesh Mahajan, Company Secretary and Compliance Officer;
Email: investors@pcdiagnostics.in;
Website: www.pcdiagnostics.in;
Corporate Identification Number: U86100MH2023PLC414723

REGISTRAR TO THE ISSUE CONTACT DETAILS
BIGSHARE SERVICES PRIVATE LIMITED
Office No. S6-2, 6th Floor, Pinnacle Business Park, next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai - 400 093, Maharashtra, India
Telephone: 022 - 6263 8200
Email: ipo@bigshareonline.com
Investor Grievance e-mail: investor@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Babu Raphael C
SEBI Registration Number: INR000001385

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

| | |
|--|---|
|  (Please scan this QR code to view the RHP) | This is an Abridged Prospectus containing salient features of the Red Herring Prospectus of Invicta Diagnostic Limited (the “Company”) dated November 24, 2025 filed with the Registrar of Companies, Mumbai at Maharashtra (the “RHP” or “Red Herring Prospectus”). You are encouraged to read greater details available in the RHP, which is available at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents . Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to then in RHP. This abridged prospectus is not for distribution outside India. THIS ABRIDGED PROSPECTUS CONSISTS OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES. |
| Please ensure that you have read the RHP, this Abridged Prospectus (“Abridged Prospectus”) and the General Information Document for investing in public issues (“GID”) undertaken through the Book Building Process before applying in the Issue (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchange, Member of the Syndicate, Registrar to the Issue, Registrar and Share Transfer Agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Bankers to the Issue, Investors’ Associations or Self Certified Syndicate Banks (“SCSBs”). You may also download the RHP from the website of Securities and Exchange Board of India (“SEBI”) at www.sebi.gov.in , the website of National Stock Exchange of India Limited (“NSE”, the “Stock Exchange”) at www.nseindia.com , and the website of the Company at www.pcdiagnostics.in and the website of the Book Running Lead Manager at https://socradamus.in/ . | |



INVICTA DIAGNOSTIC LIMITED

Corporate Identification Number: U86100MH2023PLC414723; Date of Incorporation: December 01, 2023

| Registered Office | Corporate Office | Contact Person | Email and Telephone | Website |
|---|---|--|---|--|
| 1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013, Maharashtra, India | Office No. 1012, 10 th Floor, Hubtown Viva CHS Ltd, Western Express Highway, Mogra Village, Near Shankar Wadi, Jogeshwari East, Mumbai – 400 060, Maharashtra, India | Soniya Niles Mahajan Company Secretary and Compliance Officer | Email: investors@pcdiagnostics.in Telephone: 022 - 4971 0036 | www.pcdiagnostics.in |

THE PROMOTERS OF OUR COMPANY ARE DR. KETAN JAYANTILAL JAIN, DR. SANKET VINOD JAIN, ROHIT PRAKASH SRIVASTAVA, BADAL KAILASH NAREDI AND JAYESH PRAKASH JAIN

| Details of the Issue to the Public | | | | | | | |
|------------------------------------|--|---------------------|---|--|---------------------------------|---------------------------------|---------------------------------|
| Type of Offer | Fresh Issue Size | Offer For Sale Size | Total Issue Size | Eligibility and Reservation among QIBs, NIIs & IBs | Share Reservation | | |
| | | | | | QIB | NIB | IB |
| Fresh Issue | Up to 33,08,800 Equity Shares of face value of ₹10/- each aggregating to ₹ [●] Lakhs | Not Applicable | Up to 33,08,800 Equity Shares of face value of ₹10/- aggregating to ₹ [●] Lakhs | The Issue is being made pursuant to Regulation 229 (2) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) For further details, see “Other Regulatory and Statutory Disclosures – Eligibility for the Issue” on page 289. For details of share reservation among QIBs, NIIs and IBs, see “Issue Structure” on page 307. | Not more than [●] Equity Shares | Not less than [●] Equity Shares | Not less than [●] Equity Shares |

These equity shares are proposed to be listed on SME Platform of National Stock Exchange of India Limited (“NSE EmERGE”). For the purpose of the Issue, NSE is the Designated Stock Exchange (“the Designated Stock Exchange”).

| DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION | | | |
|--|------|-----------------------------|--|
| Name of Selling Shareholder | Type | No of Equity Shares offered | Weighted average cost of acquisition per Equity Share (in ₹) |
| NA | NA | NA | NA |

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES

| | |
|--|---|
| Price Band (For details of the Price Band and the basis for the Issue Price, please refer to the price band advertisement and the section titled “Basis for Issue Price” on page 111 of the RHP) | ₹80/- per Equity Share to ₹85/- per Equity Share of face value of ₹10/- each |
| Minimum Bid Lot Size | A minimum of 3200 Equity Shares and in multiples of 1600 Equity Shares thereafter |
| Bid/ Issue Open On | Monday, 01 December, 2025 |
| Bid/ Issue Closes On* | Wednesday, 03 December, 2025 |
| Finalisation of Basis of Allotment with the Designated Stock Exchange | On or before Thursday, 04 December, 2025 |
| Initiation of Refunds (if any, for Anchor Investors)/ unblocking of funds from ASBA Account | On or before Friday, 05 December, 2025 |
| Credit of Equity Shares to Demat accounts of Allottees | On or before Friday, 05 December, 2025 |
| Commencement of trading of Equity Shares on the Stock Exchange | On or before Monday, 08 December, 2025 |

* UPI mandate end time and date shall be at 5.00 p.m. on the Bid Closing Date.

Weighted Average Cost of Acquisition of all shares transacted 18 months preceding the date of this Red Herring Prospectus

| Period | Number of Equity Shares transacted of face value ₹ 10 each | Weighted average cost of acquisition per Equity Share (in ₹) | Cap Price is ‘x’ times the weighted average cost of acquisition | Range of acquisition price per Equity Share: lowest price-highest price (in ₹) |
|---|--|--|---|--|
| Trailing Eighteen Months from the date of RHP | 8,45,253 | 71.00 | 1.20 | 71.00 - 71.00 |

*As certified by M/s Kanak Rathod and Co, Chartered Accountants, by way of their certificate dated November 18, 2025.

Disclaimer: The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”) and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities law. Accordingly, the Equity Shares are only being offered and sold outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. There will be no offering of securities in the United States.

RISKS IN RELATION TO THE FIRST ISSUE

The face value of the Equity Shares is ₹10/- each. The Floor Price, Cap Price and Issue Price determined by our Company in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated in “Basis for Issue Price” on page 111 of RHP should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and / or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 42 of RHP and on page 8 of this Abridged Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchange, Syndicate Members, Registrar to the Issue, RTAs, CDPs, Registered Brokers, Underwriters, Bankers to the Issue, Investors' Associations or SCSBs.

If you wish to know about processes and procedures applicable to this Issue, you may request for a copy of the RHP and/or the GID from the BRLM or download it from the websites of the SEBI at www.sebi.gov.in and NSE at www.nseindia.com and from the website of the BRLM at <https://socradamus.in>.

PRICE INFORMATION OF BRLM

PRICE INFORMATION OF BRLM: SOCRADAMUS CAPITAL PRIVATE LIMITED

| Sr. No. | Issue name | Issue size (₹ Crores) | Issue price (₹) | Listing Date | Opening price on Listing Date (₹) | +/- % change in closing price, [+/- % change in Closing benchmark] 30 th calendar days from listing | +/- % change in closing price, [+/- % change in closing benchmark] 90 th calendar days from listing | +/- % change in closing price, [+/- % change in Closing benchmark] 180 th calendar days from listing |
|----------------|----------------------------------|-----------------------|-----------------|-------------------|-----------------------------------|--|--|---|
| SME IPO | | | | | | | | |
| 1. | Identical Brains Studios Limited | 19.95 | 54.00 | December 26, 2024 | 95.00 | -4.63%, [-2.77%] | -16.94%, [-0.34%] | -21.20%, [-5.14%] |
| 2. | Kaytex Fabrics Limited | 69.81 | 180.00 | August 05, 2025 | 144.00 | -37.39%, [0.37%] | -50.83%, [4.52%] | N.A. |

Source: www.nseindia.com

| | |
|---|---|
| Book Running Lead Manager | Socradamus Capital Private Limited Telephone: 022 - 4961 4235 Email: info@socradamus.in Investors Grievance e-mail: investors@socradamus.in |
| Name of Syndicate Member | Nikunj Stock Brokers Limited |
| Name of Market Maker | Nikunj Stock Brokers Limited Telephone: 011 - 4703 0017/9811322534 Email: complianceofficer@nikunjonline.com |
| Name of Registrar to the Issue | Bigshare Services Private Limited Telephone: 022 - 6263 8200 Email: ipo@bigshareonline.com Investor Grievance e-mail: investor@bigshareonline.com |
| Name of Statutory Auditor | M/s. Kanak Rathod & Co, Chartered Accountants |
| Name of Credit Rating Agency and the rating or grading obtained, if any | Not Applicable |
| Name of Debenture trustee, if any | Not Applicable |
| Self-Certified Syndicate Banks | The banks registered with SEBI, offering services: (a) in relation to ASBA (other than using the UPI Mechanism), a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=34 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35 , as applicable or such other website as may be prescribed by SEBI from time to time; and (b) in relation to ASBA (using the UPI Mechanism), a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40 , or such other website as may be prescribed by SEBI from time to time. |
| SCSBs enabled for UPI Mechanism and eligible mobile application | In accordance with SEBI RTA Master Circular, UPI Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43 respectively, as updated from time to time. |
| Syndicate SCSB Branches | In relation to Bids (other than Bids by Anchor Investor) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35 and updated from time to time. For more information on such branches collecting Bid cum Application Forms from the Syndicate at Specified Locations, see the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35 as updated from time to time. |
| Registered Brokers | Bidders can submit ASBA Forms in the Issue using the stockbroker network of the stock exchange, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms, including details such as postal address, telephone number and e-mail address, is provided on the website of the Stock Exchange at www.nseindia.com , as updated from time to time. |
| Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable | The list of the RTAs eligible to accept ASBA Forms from Bidders (other than IBs) at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the website of Stock Exchange at http://www.nseindia.com/products-services/initial-public-offerings-asba-procedures , as updated from time to time. The list of the CDPs eligible to accept ASBA Forms from Bidders (other than IBs) at the Designated CDP Locations, including details such as name and contact details, is provided on the website of NSE at http://www.nseindia.com/products-services/initial-public-offerings-asba-procedures , as updated from time to time. For further details, see "Issue Procedure" at page 311 of the RHP. |

PROMOTERS OF OUR COMPANY

| Sr. No. | Name | Individual/ Corporate | Experience & Educational Qualification |
|---------|---------------------------|-----------------------|---|
| 1. | Dr. Ketan Jayantilal Jain | Individual | Dr. Ketan Jayantilal Jain is the Non-Executive Director on the Board of our Company. He holds a degree in M.B.B.S from Maharashtra University of Health Sciences, Nashik and Diploma in Medical Radiology and Electrology from College of Physicians & Surgeons of Mumbai. He has around 16 years of experience as consultant radiologist with various hospitals and diagnostic centres in past and has founded and managed a diagnostic facility, Asian Imaging for more than a decade. He is associated as consultant radiologist with one of our group companies, Primacare Diagnostic LLP and is also a consultant radiologist with our company since 2021. His role includes ensuring quality assurance and regulatory compliance of our diagnostic centres. |
| 2. | Dr. Sanket Vinod Jain | Individual | Dr. Sanket Vinod Jain is the Chairman and Non-Executive Director on the Board of our Company. He holds the Degree of M.B.B.S. from MGM Institute of Health Sciences and a M.D. (Radiodiagnosis) from Bharati Vidyapeeth Deemed University, Pune. He has approximately 6 years of experience as a consultant radiologist. He is associated as a consultant radiologist with one of our group companies, Primacare Healthcare LLP since 2019, and is also a |

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

| | | | |
|----|---------------------------------|------------|--|
| | | | consultant radiologist with our Company since 2021. He looks for performing and interpreting diagnostic imaging procedures, collaborating with physicians to develop treatment plans, and ensuring the accuracy and quality of radiology reports. |
| 3. | Rohit Prakash Srivastava | Individual | Rohit Prakash Srivastava is the Chief Financial Officer of our Company. He holds a Post Graduate Diploma in Management from Symbiosis Centre for Management and Human Resources Development, Pune and a Bachelor of Commerce from University of Mumbai. He has around 20 years of experience across various industries, including Investment Banking, Education, Wealth Management, and Healthcare with expertise in building relationships with High-Net-Worth Individuals, leading teams, and conducting financial structuring. He was previously associated with Axis Bank Limited, Lotus Wealth Advisors Pvt Ltd, IndusInd Bank Limited, The Hongkong and Shanghai Banking Corporation and Canara HSBC OBC Life Insurance Company Limited. He has also co-founded the International School of Business Administration, Pune, where he played a pivotal role in its establishment and growth, showcasing his skills in marketing, finance, and operations management. Prior to joining our company as a full time, he acted as a management advisor to our company since the incorporation of our Erstwhile LLP and then joined as Head – Business Development in February 2023. Currently, as Chief Financial Officer, he looks after the entire operations and finance including expansion, business growth, and profitability of our multi-chain diagnostic centres. |
| 4. | Badal Kailash Naredi | Individual | Badal Kailash Naredi is the Promoter of our Company. He is a Chartered Accountant by qualification and has completed his Masters and Bachelors in Commerce from University of Mumbai. He has around 20 years of experience in Investment Banking and Finance. He is currently associated with Palco Metals Limited as the Chief Financial Officer. |
| 5. | Jayesh Prakash Jain | Individual | Jayesh Prakash Jain is the Promoter of our Company. He has completed his Bachelors in Commerce from University of Mumbai. He has around 18 years of experience in gold jewellery business and was associated with Sanket Jewellers LLP since 2005 as Designated Partner. |

For details in respect of our Promoters, please see the section titled “Our Promoters and Promoter Group” beginning on page 227 of the RHP.

OUR BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are a diagnostic chain in Mumbai Metropolitan Region (“MMR”) offering comprehensive radiology and pathology solutions. We offer solution for pathology and radiology testing services such as imaging (including radiology) and pathology/clinical laboratory to customers under the brand name “PC Diagnostics” through our extensive operational network, which consists of 7 diagnostic centres including 1 centralised laboratory across Mumbai Metropolitan Region in the state of Maharashtra.

Product/Service Offering: Our company offerings are diagnostic services across pathology and radiology through a hub-and-spoke network of centres and a centralised laboratory, offering routine and specialized tests supported by advanced imaging modalities and efficient logistics.

Revenue segmentation by product/service offering:

Following is our revenue from operations for periods indicated based on our type of services:

Based on Restated Consolidated Financial Information:

(₹ in lakhs)

| Particulars | For the period ended | | For the year ended on March 31 | | | |
|--------------|-------------------------|------------------------------------|--------------------------------|------------------------------------|-------------------------|------------------------------------|
| | September 30, 2025 | | 2025 | | 2024 | |
| | Revenue from Operations | % of Total Revenue from Operations | Revenue from Operations | % of Total Revenue from Operations | Revenue from Operations | % of Total Revenue from Operations |
| Radiology | 1,526.10 | 90.05% | 2,719.27 | 90.36% | 1,487.71 | 93.98% |
| Pathology | 168.63 | 9.95% | 290.25 | 9.64% | 95.34 | 6.02% |
| Total | 1,694.73 | 100.00% | 3,009.52 | 100.00% | 1,583.05 | 100.00% |

As certified by M/s. Kanak Rathod & Co., Chartered Accountants, by way of their certificate dated November 18, 2025.

Based on Restated Standalone Financial Information:

(₹ in lakhs)

| Particulars | For the period ended on | | For the year ended on March 31 | | | | | |
|--------------|-------------------------|------------------------------------|--------------------------------|------------------------------------|-------------------------|------------------------------------|-------------------------|------------------------------------|
| | September 30, 2025 | | 2025 | | 2024 | | 2023 | |
| | Revenue from Operations | % of Total Revenue from Operations | Revenue from Operations | % of Total Revenue from Operations | Revenue from Operations | % of Total Revenue from Operations | Revenue from Operations | % of Total Revenue from Operations |
| Radiology | 949.47 | 89.38% | 1,433.34 | 88.10% | 905.06 | 93.46% | 673.18 | 98.38% |
| Pathology | 112.85 | 10.62% | 193.67 | 11.90% | 63.30 | 6.54% | 11.11 | 1.62% |
| Total | 1,062.32 | 100.00% | 1,627.02 | 100.00% | 968.36 | 100.00% | 684.29 | 100.00% |

As certified by M/s. Kanak Rathod & Co., Chartered Accountants, by way of their certificate dated November 18, 2025.

For further details, see “Our Business – Our Diagnostic Services” on page 178 of the RHP.

Geographies Served: Our Company caters to domestic markets for our services.

Revenue segmentation by geographies: NA

Key Performance Indicators:

Based on Restated Consolidated Financial Information:

a) **Key financial indicators**

| Indicator | For the Period ended | For the year ended | |
|---|--------------------------------------|--------------------|----------|
| | April 01, 2025 to September 30, 2025 | 2025 | 2024 |
| Revenue from Operations (₹ in Lakhs) ⁽¹⁾ | 1,694.73 | 3,009.52 | 1,583.05 |
| EBITDA (₹ in Lakhs) ⁽²⁾ | 676.50 | 919.89 | 708.68 |
| EBITDA Margin (%) ⁽³⁾ | 39.92% | 30.57% | 44.77% |
| PAT (₹ in Lakhs) ⁽⁴⁾ | 408.41 | 492.95 | 380.54 |
| PAT Margin (%) ⁽⁵⁾ | 24.10% | 16.38% | 24.04% |
| Return on equity (%) ⁽⁶⁾ | 21.91% | 44.28% | 55.53% |
| Return on capital employed (%) ⁽⁷⁾ | 22.80% | 42.00% | 56.04% |
| Investment in Property, Plant and Equipment during the year (₹ in Lakhs) ⁽⁸⁾ | 737.40 | 55.58 | 45.37 |
| Cash Conversion Ratio (times) ⁽⁹⁾ | 0.74 | 0.71 | 0.90 |

Notes:

(1) Revenue from operations is calculated as revenue from sale of services.

(2) EBITDA is calculated as restated profit before tax, extraordinary and exceptional items plus finance costs, depreciation and amortisation expense minus other income.

(3) EBITDA margin is calculated as a percentage of EBITDA divided by revenue from operations.

(4) PAT represents total profit after tax for the year/period.

(5) PAT margin is calculated as a percentage of PAT divided by revenue from operations.

- (6) Return on Equity (ROE%) is calculated as a percentage of PAT divided by Average Total Equity at the end of the year /period, whereas Average total equity is calculated as average of opening equity share capital and reserves and surplus and closing equity share capital and reserves and surplus.
- (7) Return on Capital Employed (ROCE%) is calculated as a percentage of EBIT is divided by Average Capital Employed at the end of the year /period, whereas Average capital employed is calculated as average of opening capital employed and closing capital employed. EBIT is calculated as restated profit before tax plus finance costs minus other income. Capital Employed is calculated as Total Equity plus DTA minus DTL, Long Term Borrowings and Short-Term Borrowings.
- (8) Investment in Property, Plant and Equipment is calculated as investment in Computers & Printers, Furniture and Fixtures, Medical Equipment, Office Equipment and Vehicles in a particular period/ year.
- (9) Cash conversion ratio is calculated as cash flow from operations divided by EBITDA.

b) Key operational indicators

| Indicator | For the period ended | For the year ended | |
|--|--------------------------------------|--------------------|------------|
| | April 01, 2025 to September 30, 2025 | 2025 | 2024 |
| Number of diagnostic centres | 7 | 7 | 8 |
| Number of patients served | 51,476 | 1,03,602 | 42,129 |
| Number of tests performed | 87,307 | 1,76,248 | 73,372 |
| Number of tests per patient visit ⁽¹⁾ | 1.70 | 1.70 | 1.74 |
| Individual Consumer Business Revenue (₹ in Lakhs) | 1,396.85 | 2,610.56 | 1,467.01 |
| Individual Consumer Business as a % of total revenue | 82.42% | 86.74% | 92.67% |
| Institutional Business Revenue (₹ in Lakhs) | 297.88 | 398.96 | 116.04 |
| Institutional Business Revenue as a % of total revenue | 17.58% | 13.26% | 6.33% |
| Average revenue per test (ARPT) (₹) ⁽²⁾ | 1,941.12/- | 1,707.55/- | 2,157.57/- |
| Revenue generated from pathology routine and specialized tests (₹ in Lakhs) ⁽³⁾ | 168.63 | 290.25 | 95.34 |
| Revenue generated from basic radiology tests (₹ in Lakhs) ⁽⁴⁾ | 302.71 | 583.56 | 277.47 |
| Revenue generated from advanced radiology tests (₹ in Lakhs) ⁽⁵⁾ | 1,223.39 | 2,135.71 | 1,210.24 |

Notes:

- (1) Number of tests per patient visit is derived by dividing the number of tests performed by the number of patients served.
- (2) Average revenue per test is calculated as revenue from operations divided by the number of tests performed.
- (3) Routine tests include: basic biochemistry, basic haematology, clinical pathology and Specialized tests are advanced biochemistry, chemiluminescence immunoassay (CLIA) that combine chemiluminescence technique with immunochemical reactions.
- (4) Basic Radiology tests include ECG, X-rays, and ultrasounds.
- (5) Advance Radiology tests include CT scans and MRI scans and highly specialized nuclear medicine tests such as PET-CT scans, which require advanced machinery to conduct such tests.

As certified by M/s Kanak Rathod and Co, Chartered Accountants, by way of their certificate dated November 18, 2025.

Based on Restated Standalone Financial Information:

a) Key financial indicators

| Indicator | For the period ended | For the year ended | | |
|---|--------------------------------------|--------------------|--------|--------|
| | April 01, 2025 to September 30, 2025 | 2025 | 2024 | 2023 |
| Revenue from Operations (₹ in Lakhs) ⁽¹⁾ | 1,062.32 | 1,627.02 | 968.36 | 684.29 |
| EBITDA (₹ in Lakhs) ⁽²⁾ | 457.13 | 620.56 | 393.85 | 170.01 |
| EBITDA Margin (%) ⁽³⁾ | 43.03% | 38.14% | 40.67% | 24.84% |
| PAT (₹ in Lakhs) ⁽⁴⁾ | 366.54 | 522.74 | 400.55 | 23.66 |
| PAT Margin (%) ⁽⁵⁾ | 34.50% | 32.13% | 41.36% | 3.46% |
| Return on equity (%) ⁽⁶⁾ | 20.81% | 51.41% | 63.62% | 4.17% |
| Return on capital employed (%) ⁽⁷⁾ | 19.85% | 41.66% | 37.99% | 5.75% |
| Investment in Property, Plant and Equipment during the year (₹ in Lakhs) ⁽⁸⁾ | 507.76 | 21.00 | 45.37 | 8.74 |
| Cash Conversion Ratio (times) ⁽⁹⁾ | 1.27 | 0.45 | 0.84 | 1.00 |

Notes:

- (1) Revenue from operations is calculated as revenue from sale of services.
- (2) EBITDA is calculated as restated profit before tax, extraordinary and exceptional items plus finance costs, depreciation and amortisation expense minus other income.
- (3) EBITDA margin is calculated as a percentage of EBITDA divided by revenue from operations.
- (4) PAT represents total profit after tax for the year/period.
- (5) PAT margin is calculated as a percentage of PAT divided by revenue from operations.
- (6) Return on Equity (ROE%) is calculated as a percentage of PAT divided by Average Total Equity at the end of the year /period, whereas Average total equity is calculated as average of opening equity share capital and reserves and surplus and closing equity share capital and reserves and surplus.
- (7) Return on Capital Employed (ROCE%) is calculated as a percentage of EBIT is divided by Average Capital Employed at the end of the year /period, whereas Average capital employed is calculated as average of opening capital employed and closing capital employed. EBIT is calculated as restated profit before tax plus finance costs minus other income. Capital Employed is calculated as Total Equity plus DTA minus DTL, Long Term Borrowings and Short-Term Borrowings.
- (8) Investment in Property, Plant and Equipment is calculated as investment in Computers & Printers, Furniture and Fixtures, Medical Equipment, Office Equipment and Vehicles in a particular period/ year.
- (9) Cash conversion ratio is calculated as cash flow from operations divided by EBITDA.

b) Key operational indicators

| Indicator | For the period ended | For the year ended | | |
|--|--------------------------------------|--------------------|-----------|--------|
| | April 01, 2025 to September 30, 2025 | 2025 | 2024 | 2023 |
| Number of diagnostic centres | 3 | 3 | 4 | 1 |
| Number of patients served | 25,606 | 56,018 | 24,408 | 14,498 |
| Number of tests performed | 52,069 | 1,00,676 | 43,146 | 20,863 |
| Number of tests per patient visit ⁽¹⁾ | 2.03 | 1.80 | 1.77 | 1.44 |
| Individual Consumer Business Revenue (₹ in Lakhs) | 846.65 | 1,414.82 | 877.88 | 658.59 |
| Individual Consumer Business Revenue as a % of total revenue | 79.70% | 86.96% | 90.66% | 96.24% |
| Institutional Business Revenue (₹ in Lakhs) | 215.67 | 212.20 | 90.48 | 25.71 |
| Institutional Business Revenue as a % of total revenue | 20.30% | 13.04% | 9.34% | 3.76% |
| Average revenue per test (ARPT) (₹) ⁽²⁾ | 2,040.21/- | 1,616/- | 2,214.2/- | 3280/- |
| Revenue generated from pathology routine and specialized tests (₹ in Lakhs) ⁽³⁾ | 112.85 | 193.67 | 63.30 | 11.11 |
| Revenue generated from basic radiology tests (₹ in Lakhs) ⁽⁴⁾ | 131.34 | 260.02 | 166.87 | 112.02 |
| Revenue generated from advanced radiology tests (₹ in Lakhs) ⁽⁵⁾ | 818.13 | 1,173.33 | 738.19 | 561.16 |

Notes:

- (1) Number of tests per patient visit is derived by dividing the number of tests performed by the number of patients served.
- (2) Average revenue per test is calculated as revenue from operations divided by the number of tests performed.
- (3) Routine tests include: basic biochemistry, basic haematology, clinical pathology and Specialized tests are advanced biochemistry, chemiluminescence immunoassay (CLIA) that combine chemiluminescence technique with immunochemical reactions.
- (4) Basic Radiology tests include ECG, X-rays, and ultrasounds.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

(5) Advance Radiology tests include CT scans and MRI scans and highly specialized nuclear medicine tests such as PET-CT scans, which require advanced machinery to conduct such tests.

As certified by M/s Kanak Rathod and Co, Chartered Accountants, by way of their certificate dated November 18, 2025.

For further details, see “Basis of Issue Price” on page 111 of the RHP.

Industries Served: We serve customers across diagnostic services to identify health conditions, ensuring accurate diagnosis, treatment planning and recovery. Catering to B2B (hospitals, clinics) and B2C (direct customers), these services are segmented into Pathology and Radiology.

Revenue segmentation in terms of top 5/10 clients or Industries: Not Applicable

Intellectual Property, if any: For details of Intellectual Property, see “Our Business – Intellectual Property” on page 188 of the RHP.

Market Share: Not ascertainable.

Manufacturing plant, if any: Not Applicable as we are in service industry.

Employee Strength: As on October 31, 2025, we have 113 full-time employees and 24 regular consultants on retainer basis and 20 Contractual employees, including 5 Key Managerial Personnel & Senior Management Personnel, 4 lab doctors, 18 radiologists and 130 technical staff and phlebotomists.

BOARD OF DIRECTORS

| Sr No. | Name | Designation | Experience & Educational Qualification | Other Directorships |
|--------|---------------------------|-------------------------------------|---|---|
| 1. | Dr. Ketan Jayantilal Jain | Non-Executive Director | Dr. Ketan Jayantilal Jain, Non-Executive Director, holds an M.B.B.S. and a Diploma in Medical Radiology and Electrology and has around 16 years of experience as a consultant radiologist, including founding and managing Asian Imaging for over a decade. | Indian companies: 1. Porteus Medical LLP (Formerly known as “Porteus Path Lab LLP”) 2. Primacare Diagnostic LLP Foreign companies: Nil |
| 2. | Dr. Sanket Vinod Jain | Chairman and Non-Executive Director | Dr. Sanket Vinod Jain, Chairman and Non-Executive Director, holds an M.B.B.S. and an M.D. (Radiodiagnosis) and has around six years of experience as a consultant radiologist with Primacare Healthcare LLP since 2019 and with our Company since 2021. | Indian companies: 1. MSCRIBEIT Infotech LLP (Formerly known as “PCD MedicalLLP”) 2. Porteus Medical LLP (Formerly known as “Porteus Path Lab LLP”) 3. Primacare Diagnostic LLP 4. Primacare Healthcare LLP 5. PCD Diagnostics LLP 6. Invicta Medical LLP Foreign companies: Nil |
| 3. | Aayush Kamleshbhai Shah | Independent Director | Aayush Kamleshbhai Shah, Independent Director, is an Associate Member of ICSI and holds Bachelor of Laws and Bachelor of Commerce degrees. He is Company Secretary of Wealth First Portfolio Managers Limited since 2015 and has 10 years’ experience in corporate and securities laws. | Indian companies: 1. H.M. Electro Mech Limited 2. Katex Exim Limited 3. Siddhi Cotspin Limited 4. Fonebox Retail Limited Foreign companies: Nil |
| 4. | Shilpa Ajay Bhatia | Independent Director | Shilpa Ajay Bhatia, Independent Director, is a Practicing Company Secretary, Associate Member of ICSI, and holds Bachelor of Laws and Bachelor of Commerce degrees. She has around 17 years’ experience in secretarial and corporate laws, restructuring, mergers, amalgamations and fundraising. | Indian companies: 1. Nibe Ordnance and Maritime Limited 2. Coastal Marine Construction and Engineering Limited 3. HREL Real Estate Limited 4. Progrex Ventures Limited Foreign companies: Nil |

For the complete profile of our Board of Directors, please refer to the chapter title “Our Management - Brief profile of our directors” beginning on page 211 of the RHP.

OBJECTS OF THE ISSUE

The Issue comprises of a Fresh Issue of up to 33,08,800 Equity Shares aggregating up to ₹ [●] Lakhs, subject to finalization of Basis of Allotment. For details, see “Summary of the Offer Document” and “The Issue” on pages 28 and 70, respectively.

Proposed schedule of implementation and deployment of Net Proceeds:

| Sr. No. | Object | Amount to be funded from Net Proceeds (₹ in Lakhs) | Amount to be deployed from the Net Proceeds in Fiscal 2026 | Amount to be deployed from the Net Proceeds in Fiscal 2027 |
|---------|--|--|--|--|
| 1. | Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; | 2,111.33 | 879.35 | 1,231.98 |
| 2. | General Corporate Purposes [#] | [●] | [●] | [●] |
| | Total | [●] | [●] | [●] |

[#] To be finalized upon determination of the Issue Price and updated in the Prospectus prior to filing with ROC. The amount utilized for general corporate purpose shall not exceed 15 % of the Gross Proceeds of the Issue or ₹ 1,000.00 lakhs whichever is lower.

For further details, see “Objects of the Issue” on page 101 of the RHP.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: NA

Name of monitoring agency, if any: Not Applicable

Terms of Issuance of Convertible Security, if any: Not Applicable

Shareholding Pattern as on the date of the RHP:

| Sr. No. | Particulars | Pre-Issue number of Equity Shares (Number of fully paid-up Equity Shares held) | % Holding of Pre-Issue (Shareholding as a % of total number of shares) |
|---------|----------------------------|--|--|
| 1. | Promoters & Promoter Group | 83,84,920 | 90.52% |
| 2. | Public | 8,78,253 | 9.48% |
| | Total | 92,63,173 | 100.00% |

Number/amount of equity shares proposed to be sold by selling Shareholders, if any: Not Applicable

SUMMARY OF RESTATED FINANCIAL INFORMATION

Based on standalone:

(₹ in Lakhs)

| Particulars | For the period ended on | For the year ended 31 st March | | |
|------------------------------------|-------------------------|---|--------|--------|
| | September 30, 2025 | 2025 | 2024 | 2023 |
| Total income from operations (Net) | 1,062.32 | 1,627.02 | 968.36 | 684.29 |

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

| | | | | |
|---|----------|----------|--------|--------|
| Net Profit/(Loss) before tax and extraordinary items | 485.10 | 668.39 | 472.08 | 31.62 |
| Net Profit / (Loss) after tax and extraordinary items | 366.54 | 522.74 | 400.55 | 23.66 |
| Equity Share Capital | 926.32 | 841.79 | 13.15 | 503.68 |
| Reserve & Surplus | 1,318.55 | 436.41 | 742.31 | - |
| Net worth | 2,244.87 | 1,278.20 | 755.46 | 503.68 |
| Basic and Diluted earnings per share (₹) | 4.12 | 6.21 | 4.76 | 0.28 |
| Return on net worth (%) | 16.33% | 40.90% | 53.02% | 4.70% |
| Net asset value per share (₹) | 25.22 | 15.18 | 8.97 | 5.98 |

Based on consolidated:

(₹ in Lakhs)

| Particulars | For the period ended on | For the year ended 31 st March | |
|---|-------------------------|---|----------|
| | September 30, 2025 | 2025 | 2024 |
| Total income from operations (Net) | 1,694.73 | 3,009.52 | 1,583.05 |
| Net Profit/(Loss) before tax and extraordinary items | 542.85 | 656.36 | 512.09 |
| Net Profit / (Loss) after tax and extraordinary items | 408.41 | 492.95 | 380.54 |
| Equity Share Capital | 926.32 | 841.79 | 13.15 |
| Reserve & Surplus | 1,442.06 | 518.05 | 853.74 |
| Net worth | 2,368.38 | 1,359.85 | 866.89 |
| Basic and Diluted earnings per share (₹) | 4.59 | 5.86 | 4.52 |
| Return on net worth (%) | 17.24% | 36.25% | 43.90% |
| Net asset value per share (₹) | 26.60 | 16.15 | 10.30 |

INTERNAL RISK FACTORS

The below mentioned risks are top 10 risk factors as per the Prospectus:

1. Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.
2. Any interruptions at our flagship centre and other diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.
3. Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects.
4. Our operations are concentrated in Mumbai Metropolitan Region ("MMR"), and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
5. Our ability to remain competitive may be adversely affected by technological advancements, innovations in diagnostic testing and our ability to access such technology.
6. We operate in a highly competitive business environment, and our inability to compete effectively could have an adverse effect on our business, results of operations and financial condition.
7. Failure to establish and comply with appropriate quality standards when performing imaging, testing and diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.
8. We may be unable to successfully implement or manage our growth strategy.
9. The Restated Financial Information provided in this Draft Red Herring Prospectus have been provided by the Peer Reviewed Chartered Accountants who are not the Statutory Auditors of our Company.
10. The industry in which we operate possess various risks and challenges as provided in the Industry Report titled "Industry Report on Diagnostic Industry in India" dated July 22, 2024, which is exclusively prepared for the purposes of the Offer and issued by D&B and is commissioned and paid for by our Company ("D&B Report").

For further details, see "Risk Factors" beginning on page 42 of the RHP.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total number of outstanding litigations against our Company and amount involved:

| Name of Entity | Criminal Proceedings | Tax Proceedings | Statutory or Regulatory Proceedings | Disciplinary actions by the SEBI or Stock Exchanges against our Promoters | Material Civil Litigations | Aggregate amount Involved (Rs in Lakhs) |
|---|----------------------|-----------------|-------------------------------------|---|----------------------------|---|
| Company | | | | | | |
| By the Company | Nil | Nil | Nil | Nil | Nil | Nil |
| Against the Company | Nil | 2 | Nil | Nil | Nil | 0.002 |
| Promoters | | | | | | |
| By Promoters | Nil | Nil | Nil | Nil | Nil | Nil |
| Against Promoters | Nil | 8 | Nil | Nil | Nil | 0.602 |
| Directors (Other than Promoters) | | | | | | |
| By Directors | Nil | Nil | Nil | Nil | Nil | Nil |
| Against the Directors | Nil | Nil | Nil | Nil | Nil | Nil |
| Subsidiaries | | | | | | |
| By Subsidiaries | Nil | Nil | Nil | Nil | Nil | Nil |
| Against Subsidiaries | Nil | 8 | Nil | Nil | Nil | 0.98 |
| Key Managerial Personnel & Senior Management Personnel | | | | | | |
| By KMPs/ SMPs | Nil | Nil | Nil | Nil | Nil | Nil |
| Against KMPs/ SMPs | Nil | Nil | Nil | Nil | Nil | Nil |

Determined in accordance with the Materiality Policy.

B. Brief details of top 5 material outstanding litigations against the company and amount involved: Not Applicable

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: Not Applicable

D. Details of outstanding criminal proceedings against Promoters: Not Applicable

ANY OTHER IMPORTANT INFORMATION AS PER BRML / ISSUER COMPANY - NIL

DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government, or the rules, regulations or guidelines issued by SEBI, established under Section 3 of the SEBI Act, as the case may be, have been complied with, and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the SCRA, the SCRR and the SEBI Act, each as amended, or the rules made, or regulations or guidelines issued thereunder, as the case may be. We further certify that all the statements made in the Red Herring Prospectus are true and correct.

LIST OF SELF CERTIFIED SYNDICATE BANKS (SCSBs) UNDER THE ASBA PROCESS

| Sr. No. | Name of the Bank | Controlling Branch & Address | Contact Person | Telephone Number | Fax Number | Email |
|---------|---------------------------------|--|--|--|-------------------|---|
| 1. | Axis Bank Ltd. | Centralised Collections and Payment Hub (CCPH) 5th Floor, Gigaplex, Building No. 1, Plot No. I.T.5, MIDC, Airoli Knowledge Park, Airoli, Navi Mumbai - 400708 | Mr. Sunil Fadtare Assitant Vice President | 022-71315906, 9819803730 | 022- 71315994 | Sunil.fadtare@axisbank.com |
| 2. | AU Small Finance Bank Limited | CP3 235, Industrial Area, Apparel Park, Mahal Road, Jagatpura, Jaipur, Rajasthan 302022 | Vikrant Singh Sirohi | Mobile : +91 7340012357 | - | cpcasba@aubank.in |
| 3. | Bandhan Bank | Adventz Infinity@5, BN Block, Sector V, Salt Lake City, Kolkata | Sagar Ranjan Das Senior Manager | Mobile : 9022339164 | - | asba.business@bandhanbank.com |
| 4. | Bank of Baroda | Mumbai Main Office, 10/12 Mumbai Samachar Marg, Fort, Mumbai-23 | Mr. Sonu A. Arekar | 022-40468314, 40468307, | 022-22835236 | asba.fortap@bankofbaroda.com |
| 5. | Bank of Maharashtra | Fort Branch, 1st Floor, Jammangal, 45/47, Mumbai Samachar Marg, Mumbai - 400023 | SHRI. V R Kshirsagar (DGM) | 022-22694160 22652595 22663947 | 022-22681296 | brmgr2@mahabank.co.in; bom2@mahabank.co.in |
| 6. | BNP Paribas | BNP Paribas House, 1, North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400051 | Mr. Ashish. Chaturvedi, Mr. Dipu SA, Ms Prathima Madiwala | (022) 61964570/61964594/61964592 | (022) 61964595 | Ashish.chaturvedi@asia. bnpparibas.comdipu.sa@asia. bnpparibas.comprathima. madiwala@asia.bnpparibas.com |
| 7. | Barclays Bank PLC | Barclays Bank PLC 601/603 Ceejay House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai - 400018 | Parul Parmar | +91- 22 6719 6400/ 6575 | +91- 22 6719 6996 | Parul.parmar@barclays.com |
| 8. | Bank of India | Phiroze Jeejeebhoy Tower, (New Stock Exchange Bldg), P. J. Tower, Dalal Street, Fort, Mumbai - 400 023. | Shri Navin Kumar Pathak, Senior Manager | 022-22723631/1677/ 9619810717 | 022-22721782 | Stockexchange.Mumbai, south@bankofindia.co.in |
| 9. | Credit Suisse | 10th Floor, Ceejay House, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018. | Yogesh Bachwani | 098216 13306 | - | yogesh.bachwani@credit-suisse.com |
| 10. | CITI Bank NA | Citigroup Center, Plot No C-61, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 | S Girish | 022-26535504, 98199 12248 | 022-26535824 | s.girish@citi.com, asba.ops@ citi.com |
| 11. | Central Bank of India | Ground floor, Central Bank of India, Central Bank Building, Fort, Mumbai 400001 | Mr. Vineet Bansaj | 022- 22623148, 22623149 | 022-22623150 | asba4082@centralbank.co.in |
| 12. | Canara Bank | Canara Bank, Capital Market Service Branch,407, 4th floor, Himalaya House79, Mata Ramabai Ambedkar, Marg, MUMBAI-400 001 | Mr. Arvind Namdev Pawar | 022-22661618/ 22692973/ 9769303555 | 022-22664140 | cb2422@canarabank.com, mbdcomcity@canarabank.com, hocmbd@canarabank.com |
| 13. | City Union Bank Ltd. | 48, Mahalakshmi St., T. Nagar, Chennai - 600 017.Tamil Nadu. | Sivaraman | 044 - 24340010, 24343517, 24346060, 24348586, 9380286558, 9382642081 | 044 - 24348586 | cub001@cityunionbank.com |
| 14. | DBS Bank Ltd. | DBS Bank Ltd, Fort House, 221, Dr. D.N. Road, Fort, Mumbai, 400 001 | Amol Natekar | +91 22 6613 1213 | +91 22 6752 8470 | amolnatekar@db.com |
| 15. | DCB Bank | 154, S.V.Patel Road, Dongri (E), Pin - 400009. | Meenaz Hasanali Thanawala | 022-67474170 | - | meenaz@dcbbank.com |
| 16. | Dhanlaxmi Bank Limited | Ground Floor, Jammabhoomi Bhavan, Plot 11 -12, Jammabhoomi Marg, Fort Mumbai, Maharashtra - 400 001 | Ramesh Menon | 9167832288, 022- 22871658 | - | ramesh.menon@dhanbank.co.in |
| 17. | Deutsche Bank | Sidrah, 110, Swami Vivekananda Road, Khar (West), Mumbai 400052 | Ms. Hetal Dholakia | (91) (022) 6600 9428 (91) (022) 6600 9419 | - | hetal.dholakia@db.com manoj-s.naik@db.com; nanette. daryanani@db.com. |
| 18. | Equitas Small Finance Bank | CPC, Phase II, 4th floor, Spencer Plaza, No 769, Anna Salai, Chennai - 600002 | Chandrashekar Arumugam | (M) 8939886802 | - | asbaoperations@equitasbank.com; asbarecon@equitasbank.com |
| 19. | GP Parsik Sahakari Bank Limited | Shivram Patil Bhavan, Parsik Nagar, Kalwa, Thane | Mr.Mayur M.Tanksale | 022-25456655 | - | mmmtanksale800@gpparsikbank.net / pjsbasba@gpparsikbank.net |
| 20. | HSBC Ltd. | 3rd Floor, PCM Dept. Umang, Plot CTS No. 1406-A/28, Mindspace, Malad (West) Mumbai 400 064 (address of IPO Operations office) | Mr Jagrut Joshi | (022) 67115485/ 9870403732 | (022) 66536005 | jagrutjoshi@hsbc.co.in |
| 21. | HDFC Bank Ltd. | FIG - OPS Department HDFC Bank Ltd Lodha - I Think Techno Campus O-3 Level Next to Kanjurmarg Railway Station Kanjurmarg (East) Mumbai - 400042 | Vincent Dsouza / Siddharth Jadhav / Prasanna Uchil | 022-30752929 / 2927 / 2928 | - | vincent.dsouza@hdfcbank.com, siddharth.jadhav@hdfcbank.com, prasanna. uchil@hdfcbank.com |
| 22. | IDFC First Bank | Building no 2, Mindspace TTC Industrial Area, Juinagar. Navi Mumbai - 400 706 | Mr. V M Praveen | 022-49850025/ 9819708055 | - | ASBA.CB@idfcfirstbank.com |
| 23. | ICICI Bank Ltd. | ICICI BANK LIMITED, Capital Market Division, 1st Floor, 122, Mistry Bhavan, Dinshaw Vachha Road, Backbay Reclamation, Churchgate, Mumbai | Roshan Tellis | 022-22859874/803 | 022-22611138 | roshan.tellis@icicibank.com |
| 24. | IDBI Bank Ltd. | IDBI Bank Limited Central Processing Unit, Sarju House, 3rd Floor, Plot No 7, Street No. 15, Andheri MIDC, Andheri (E), Mumbai.Pin : 400093 | Shri. Naveen Nischal HP / Shri Viral Barodia | 022- 66700525 / 685 | - | hp.naveennischal@idbi.co.in / barodia.viral@idbi.co.in |
| 25. | Indian Bank | Nandanam Branch- 480 Anna Salai, Nandanam 600035 | Mr. V Muthukumar, Mr. M Veerabahu | 044 24330233 | 044 24347755 | nandanam@indianbank.co.in |
| 26. | IndusInd Bank | IndusInd Bank Ltd. Fort Branch Sonawalla Bldg, Mumbai Samachar Marg, Fort, Mumbai 400001 | Yogesh Adke Dy. Vice President | 022-66366589 / 91 / 929833670809 | 022-22644834 | yogesh.adke@indusind.com |
| 27. | Indian Overseas Bank | Mexxanine Floor, Cathedral Branch, 762 Anna Salai, Chennai 600 002 | Mr. V. Srinivasan | 044 - 28513616 | - | deposit@jobnet.co.in |
| 28. | J P Morgan Chase Bank, N.A. | J.P. Morgan Tower, Off C.S.T. Road, Kalina Santacruz - East, Mumbai - 400 098 | Mahesh Aras | 022-61573811 | 022-61573949 | Mahesh.aras@jpmorgan. comIndia.operations@jpmorgan.com |
| 29. | Janata Sahakari Bank Ltd. | N S D L Department Bharat Bhavan, 1360, Shukrawar Peth, Pune -411002 | Shri. Ajit Manohar Sane+91 9960239391 | +91 (20) 24431011 +91 (20) 24431016 +91 9503058993 | +91 (20) 24431014 | jsbnsdl@dataone.in |
| 30. | Karur Vysya Bank Ltd. | Demat Cell, Second Floor No 29, Rangan Street, T Nagar, Chennai - 600 017 | Maruthi Kumar Yenamandra | 044- 24340374 | 044-24340374 | maruthikumar@kvbmail.com, kvbdp@kvbmail.com |

| Sr. No. | Name of the Bank | Controlling Branch & Address | Contact Person | Telephone Number | Fax Number | Email |
|---------|---|--|---|---|----------------------|---|
| 31. | Karnataka Bank Ltd | The Karnataka Bank Ltd Mangalore-H O Complex Branch Mahaveera Circle Kankanady Mangalore - 575002 | Ravindranath Baglodi [Sr.Manager] | Ph: 0824-2228139 /140 /141 | Fax: 0824-2228138 | Email: mlr.hocomplex@ktkbank.com |
| 32. | Kotak Mahindra Bank Ltd. | Kotak Infinity, 6 th Floor, Building No. 21, Infinity Park, Off Western Express Highway, General AK Vaidya Marg, Malad(E) | Prashant Sawant | D-+91 22 6605 6959M-+91 9967636316 | +91 66056642 | prashant.sawant@kotak.com |
| 33. | Mehsana Urban Co-Op. Bank Ltd. | Head Office, Urban Bank Road, Highway, Mehsana - 384002 | Branch Manager | +91-2762-251908 | +91-2762-240762 | asba@mucbank.com |
| 34. | Nutan Nagrik Sahakari Bank Ltd. | Opp Samratshwar Mahadev, Nr, Law Garden, Ellisbridge, Ahmedabad-380006 | Miti Shah | 9879506795 | 7926564715 | smiti@1977@yahoo.com |
| 35. | Punjab National Bank | Capital Market Services Branch, PNB House, Fort, Sir P.M.Road Mumbai | Sh. K Kumar Raja | Tel - 022- 22621122, 22621123, | 022 - 22621124 | pnbcapsmbai@pnb.co.in |
| 36. | Punjab & Sind Bank | Rajindera Place- 21 Rajindra Place Bank House New Delhi-110008 | RPS Sandhu | 011- 25825784/25711836 9911129088 | - | d0606@psb.co.in |
| 37. | RBL Bank Limited | Techniplex - I, 9 th Floor, Off Veer Savarkar Flyover, Goregaon (West), Mumbai - 400062. | Shashikanth Sanil | 022-40288193, 022-40288196, 022-40288197 | 022-40288195 | asba_ops@rblbank.com |
| 38. | Rajkot Nagarik Sahakari Bank Ltd. | Nagrik Bhavan No 1 Parabazar Dhebarbhai Road Rajkot | Shri Yogesh Raveshiya | 9427495222 | (0281) 2233916/17/18 | khumesh@rnsbindia.com; asba@rnsbindia.com |
| 39. | State Bank of Hyderabad | Gunfoundry, Hyderabad | Sri Ashok Kulkarni | 040-23387325 | 040-23387743 | gunfoundry@sbyhd.co.in |
| 40. | State Bank of Travencore | Anakachery Buildings, Y M C A Road, Statue, Thiruvananthapuram-695001 | P. P. Muralidharan | 0471-2333676 | 0471-2338134 | dptvm@sbt.co.in |
| 41. | SVC Co-Operative Bank Ltd. | Unit No.601-602-603 Dosti Pinnacle Plot No. E-7, Road No.22, Wagle Estate, Thane 400604 | Mr. Omkar Anil Sukhathankar | (O) 71991460 71991461 71991462 71991463 71991465 | - | sukhathankaroa@svcbank.com |
| 42. | State Bank of Bikaner & Jaipur | Financial Super Market Branch, Apex Mall, Tonk Road, Jaipur | Shri N K Chandak | 0141-27444159413398505 | 0141-2744457 | sbbj11060@sbbj.co.in innkchandak@sbbj.co.in |
| 43. | State Bank of India | State Bank of India, Capital Market Branch(11777),Videocon Heritage Building(Killick House),Charanjit Rai Marg, Fort, Mumbai - 400 001. | Ms. Raviti | Telephone:022-22094932 Mobile:9870498689 | 022-22094921 | nib.11777@sbi.co.in |
| 44. | Standard Chartered Bank | Crescenzo, 3rd Floor, C/38-39, G-Block, Opposite MCA Club, Bandra-Kurla Complex, Bandra [East], Mumbai 400-051 | Rohan Ganpule | 022 - 61157250 / 022 - 61157234 | 022 -26757358 | lpo.scb@sc.com |
| 45. | Syndicate Bank | Capital Market Service Branch, 26A, First Floor, Syndicate Building, P.M. Road, Fort, Mumbai. | P Padmavathy Sundaram, Chief Manager | 022-22621844 | 022-22700997 | padmas@syndicatebank.co.in/ cmssc@syndicatebank.co.in |
| 46. | South Indian Bank | ASBA Cell (NODAL OFFICE) 2nd Floor, Shanu Towers, North Kalamassery, Ernakulam, Kerala - 683 104 | John K Mechery | 9645817905 | 0484-2351923 | asba@sib.co.in |
| 47. | State Bank of Patiala | CO 99-102, Sector - 8C, Chandigarh | Shri. Amarjit Singh Gim | 0172-2779116, 2546124, 254386809779586096 | 0172-2546080 | b5597@sbp.co.in |
| 48. | State Bank of Mysore | P. B. No. 1066. # 24/28, Cama Building, Dalal Street, Fort, Mumbai -400 001 | Shailendra kumar | 7208048007022- 22678041 | 022-22656346 | s.kumar@sbm.co.indalalst@sbm.co.in |
| 49. | The Federal Bank Limited | ASBA CELL, Retail Business Dept., Federal Bank, Marine Drive, Ernakulam 682031 | Dhanya Dominic | 0484-2201847 | 4842385605 | rbd@federalbank.co.indhanyad@federalbank.co.inriyajacob@federalbank.co.in |
| 50. | Tamilnad Mercantile Bank Ltd. | Tamilnad Mercantile Bank Ltd., Depository Participant Services Cell Third Floor, Plot No.4923, Ae/16, 2nd Avenue, Anna Nagar (West), Chennai - 600 040, Tamilnadu, India | Mr. N. Rajasegaran | 044-26192552 | 044-26204174 | dps@tmbonline.com |
| 51. | The Jammu & Kashmir Bank Ltd. | 79 A, Mehta House, Bombay Samachar Marg, Fort, Mumbai - 400 023. | Ashfaq Ahmad | 9987984105, 022-66595971 | 022-6634183 | bombay@jkbmail.com |
| 52. | The Kalupur Commercial Co-Operative Bank Ltd. | Kalupur Bank Bhavan, Nr. Income Tax Circle, Ashram Road, Ahmedabad-380 014 | Jay V. Pathak Manager | 079-27582028 | 079-27544666 | jay@kalupurbank.com |
| 53. | The Lakshmi Vilas Bank Ltd. | Bharat House, Ground Floor, 104, Bombay Samachar Marg, Fort Mumbai - 400 001. | S Ramanan | 022-22672255-22672247(M)- 22673435(CM) | 022-22670267 | MumbaiFORT_bm@lvbank.in |
| 54. | The Surat Peoples Co-op Bank Ltd | Central Office. Vasudhara Bhavan, Timaliyawad, Nanpura, Surat - 395001 | Mr. Iqbal Shaikh | 0261-2464577 | 0261-2464577,592 | Iqbal.shaikh@spcbl.in |
| 55. | The Saraswat Co-operative Bank Ltd. | Madhushree, Plot No. 85, District Business Centre, Sector - 17, Vashi, Navi Mumbai - 400703 | Mr. Ajit Babaji Satam | 022-27884161 27884162 27884163 27884164 | 022-27884153 | ab_satam@saraswatbank.com |
| 56. | TJSB Sahakari Bank Ltd | 2nd Floor, Madhukar Bhavan, Road No.16, Wagle Estate | Department Head | 022-25838525/530/520 | | tjsbasba@tjsb.co.in |
| 57. | Union Bank of India | MUMBAI SAMACHAR MARG, 66/80, Mumbai Samachar Marg, Post Bag No.253 & 518, Fort, Mumbai - 400023. | Mr. D B JAISWAR | 022-22629408 | 022- 22676685 | jaiswar@unionbankofindia.com |
| 58. | UCO Bank | Mumbai Main (Retail) Br., UCO Bank Bldg., D. N. Road, Mumbai- 400 023 | Manager | 022 40180117 9022457840 | 022-2222870754 | bo.dnroad@mtnl.net.in |
| 59. | Yes Bank Ltd. | YES Bank Limited, Indiabulls Finance Centre, Tower -II , 8th Floor, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400 013. | Alok Srivastava / Shankar Vichare / Avinash Pawar | 022 3347 7374/ 7259/ 7251 | 022 24214504 | dlbtiservices@yesbank.in |
| 60. | The Ahmedabad Mercantile Co-Op. Bank Ltd. | Head office :- "Amco House", Nr. Stadium Circle, Navrangpura, Ahmedabad-09 | Bimal P Chokshi | 079-26426582-84-88 | 079-26564863 | amcoasba@rediffmail.com |
| 61. | Catholic Syrian Bank Ltd. | P B No. 1900, Ground Floor, Marshall Annex Building, Soorji Vallabhdas Marg, Ballard Estate, Mumbai, Maharashtra, Pin-400001 | Ram Mohan G S | 022-64502165, 022-22664269, 022-22665865, 022-22650850 | - | mumbaiFORT@csb.co.in |

ASBA Applicants may approach any of the above banks for submitting their application in the issue. For the complete list of SCSBs and their Designated Branches please refer to the website of SEBI <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34>. A list of SCSBs is also displayed on the website of NSE at www.nseindia.com.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an 'indication to make an Issue' and not 'an Issue'.
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment Amount exceeds ₹ 2,00,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Issue Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, UPI Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the First Bidder is required to sign the Bid cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. Non-Institutional Bidders applying up to Rs. 500,000 can apply through UPI mode as per NPCI vide circular reference no. NPCI/UP/OC No. 127/2021-22 dated December 09, 2021 read with SEBI ICDR Master Circular.
 - UPI Bidders using UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public Issue.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 311 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgment Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof. Investors must ensure that their PAN is linked with Aadhar card and are in compliance with the CBDT notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023.

ISSUE STRUCTURE

| Particulars | Market Maker Reservation Portion | QIBs ⁽ⁱ⁾ | NIBs | IBs |
|--|--|---|---|---|
| Number of Equity Shares available for allocation / allotment ⁽ⁱⁱ⁾ | Up to [●] Equity Shares of face value of ₹10/- each | Not more than [●] Equity Shares of face value of ₹10/- each, aggregating to ₹ [●] lakhs, subject to the allocation/ allotment of not more than 50% of the Net Issue | Not less than [●] Equity Shares of face value of ₹10/- each available for allocation or issue less allocation to QIB Bidders and IBs | Not less than [●] Equity Shares of face value of ₹10/- each available for allocation or issue less allocation to QIB Bidders and NIBs |
| Percentage of Issue Size available for allotment / allocation | The Market Maker Reservation Portion shall constitute [●] % of the Issue Size | Not more than 50% of the Net Issue being available for allocation to QIB Bidders. However, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining Net QIB Portion (excluding the Anchor Investor Portion). The unsubscribed portion in the Mutual Fund Portion will be available for allocation to other QIBs | Not less than 15% of the Net Issue less allocation to QIB Bidders and IBs shall be available for allocation, subject to the following: (a) one third of the portion available to NIBs shall be reserved for bidders with a bid size of more than two lots and up to such lots equivalent to not more than ₹10.00 lakhs; and (b) two third of the portion available to NIBs shall be reserved for bidders with bid size of more than ₹10.00 lakhs. Provided that the unsubscribed portion in either the sub-categories mentioned above could be allocated to applicants in the other sub-category of NIBs | Not less than 35% of the Net Issue |
| Basis of Allotment / allocation if respective category is oversubscribed* | Firm Allotment | Proportionate as follows (Excluding the Anchor Investor Portion): a) [●] Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; b) [●] Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above; c) Up to 60% of the QIB Portion (of up to [●] Equity Shares) may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price | The Allotment of Equity Shares to each Non-Institutional Bidder shall not be less than the minimum application size, subject to availability in the Non- Institutional Portion, and the remainder, if any, shall be allotted on a proportionate basis in accordance with the conditions specified in Schedule XIII to the SEBI ICDR Regulations | The allotment to each IB shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Individual Bidder and the remaining available Equity Shares if any, shall be Allotted on a proportionate basis. See "Issue Procedure" on page 311. |
| Minimum Bid | [●] Equity Shares | Such number of Equity Shares in multiples of [●] Equity Shares such that the Bid Amount exceeds ₹2,00,000 | For NIBs applying under one-third of the Non-Institutional Portion (with bid size of more than two lots and up to such lots equivalent to not more than ₹10.00 lakhs) such number of Equity Shares in multiples of [●] Equity Shares, such that the Bid size exceeds two lots. For NIBs applying under two-thirds of the Non-Institutional Portion (with bid size of more than ₹10.00 lakhs) such number of Equity Shares in multiples of [●] Equity Shares, such that the Bid Amount exceeds ₹10.00 lakhs | 2 lots such that the Bid size shall be above ₹2 lakhs |
| Maximum Bid | [●] Equity Shares | Such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Net Issue (excluding the Anchor Investor Portion), subject to applicable limits to each Bidder | For Non-Institutional Bidders applying under one-third of the Non- Institutional Portion (with bid size of more than 2 lots and up to ₹10.00 lakhs) such number of Equity Shares in multiples of [●] Equity Shares, such that the Bid Amount does not exceed ₹10.00 lakhs. For Non-Institutional Bidders applying under two-thirds of the Non-Institutional Portion (with bid size of more than ₹10.00 lakhs) such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Issue, (excluding the QIB Portion) subject to limits applicable to the Bidder | 2 lots such that the Bid size shall be above ₹2 lakhs |
| Lot Size | [●] Equity Shares and in multiples of [●] Equity Shares thereafter | | | |
| Mode of Allotment | Compulsorily in dematerialised form | | | |
| Trading Lot | [●] Equity Shares. However, the Market Maker may buy odd lots if any in the market as required under the SEBI ICDR Regulations | [●] Equity Shares | | |
| Who can Apply ^{(iii)(iv)(v)} | Market Maker | Public financial institutions as defined in the Companies Act, 2013, scheduled commercial banks, multilateral and bilateral development financial institutions, Mutual Funds, FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCIs, state industrial development corporation, insurance company registered with IRDAI, provident funds with minimum corpus of ₹ 250 million, pension funds with minimum corpus of ₹ 250 million registered with the Pension Fund Development and Regulatory Authority, National Investment Fund set up by the GoI, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and NBFC-SI | Resident Indian individuals, Eligible NRIs, HUFs (in the name of the karta), companies, corporate bodies, scientific institutions, societies, trusts, family offices and FPIs who are individuals, corporate bodies and family offices which are re-categorised as category II FPIs and registered with SEBI | Resident Indian individuals, Eligible NRIs and HUFs (in the name of the karta) |
| Terms of Payment | In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids ^(vi) In case of all other Bidders: Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form. | | | |
| Mode of Bidding ^h | ASBA Process only (except in case of Anchor Investors) | ASBA Process only (except in case of Anchor Investors) | ASBA Process only (including the UPI Mechanism to the extent of Bids up to ₹5,00,000) | ASBA Process only (including the UPI Mechanism) |

*Assuming full subscription in the Issue

^h As per SEBI ICDR Master Circular, ASBA applications in public issues shall be processed only after the application monies are blocked in the bank accounts of the investors. Accordingly, Stock Exchanges shall, for all categories of investors viz. QIBs, NIBs and IBs and also for all modes through which the applications are processed, accept the ASBA applications in their electronic book building platform only with a mandatory confirmation on the application monies blocked.

⁽ⁱ⁾ Our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors at the Anchor Investor Issue Price, on a discretionary basis, subject to there being (i) a maximum of two Anchor Investors, where allocation in the Anchor Investor Portion is up to ₹200.00 lakhs; (ii) minimum of two and maximum of 15 Anchor Investors, where the allocation under the Anchor Investor Portion is more than ₹200.00 lakhs but up to ₹2,500.00 lakhs under the Anchor Investor Portion, subject to a minimum Allotment of ₹100.00 lakhs per Anchor Investor; and (iii) in case of allocation above ₹2,500.00 lakhs under the Anchor Investor Portion, a minimum of five such investors and a maximum of 15 Anchor Investors for allocation up to ₹2,500.00 lakhs, and an additional 10 Anchor Investors for every additional ₹2,500.00 lakhs or part thereof will be permitted, subject to minimum allotment of ₹100.00 lakhs per Anchor Investor. An Anchor Investor will make a minimum Bid of such number of Equity Shares, that the Bid Amount is at least ₹200.00 lakhs. One-third of the Anchor Investor Portion will be reserved for domestic Mutual Funds, subject to valid Bids being received at or above the price at which allocation is made to Anchor Investors, which price shall be determined by the Company in consultation with the BRLM.

⁽ⁱⁱ⁾ Subject to valid Bids being received at or above the Issue Price. This Issue is being made in accordance with Rule 19(2)(b) of the SCRR and Regulation 253(1) and 253(2) of the SEBI ICDR Regulations.

⁽ⁱⁱⁱ⁾ In the event that a Bid is submitted in joint names, the relevant Bidders should ensure that the depository account is also held in the same joint names and the names are in the same sequence in which they appear in the Bid cum Application Form. The Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such first Bidder would be required in the Bid cum Application Form and such first Bidder would be deemed to have signed on behalf of the joint holders.

^(iv) Bids by FPIs with certain structures as described under "Issue Procedure – Bids by FPIs" on page 317 and having the same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allocated and Allotted to such successful Bidders (with same PAN) may be proportionately distributed.

^(v) Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Issue Price shall be payable by the Anchor Investor Pay-in Date as indicated in the CAN.

**COMMON BID
REVISION FORM**

INVICTA DIAGNOSTIC LIMITED - INITIAL PUBLIC OFFER - NR

Registered Office: 1 GF, Plot 217, Ambavat Bhavan, N.M. Joshi Marg, Delisle Road, Mumbai - 400 013, Maharashtra, India;
Corporate Office: Office No. 1012, 10th Floor, Hubtown Viva CHS Ltd, Western Express Highway, Mogra Village, Near Shankar Wadi, Jogeshwari East, Mumbai - 400 060, Maharashtra, India;
Contact Person: Soniya Nilesh Mahajan, Company Secretary and Compliance Officer;
Telephone: 022 - 4971 0036; Email: investors@pcdiagnostics.in; Website: www.pcdiagnostics.in; Corporate Identification Number: U86100MH2023PLC414723

FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIs,
FPIs, FVCI, AND REGISTERED MULTI LATERAL AND
BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS
ETC. APPLYING ON A REPATRIATION BASIS



To,
The Board of Directors
INVICTA DIAGNOSTIC LIMITED

100% BOOK BUILT ISSUE
ISIN : INE0XJ501010

**Bid cum
Application
Form No.**

| | | | | | |
|--|--|--|--|---|--|
| MEMBERS OF THE SYNDICATE STAMP & CODE | | SUB-SYNDICATE MEMBER/ REGISTERED BROKER SCSB/CDP/RTA STAMP & CODE | | 1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER | |
| | | | | Mr. /Ms./M/s. _____ | |
| | | | | Address _____ | |
| | | | | _____ Email _____ | |
| | | | | Tel. No. (with STD code) / Mobile _____ | |
| SUB-BROKER'S / SUB-AGENT'S STAMP & CODE | | SCSB BRANCH STAMP & CODE | | 2. PAN OF SOLE / FIRST BIDDER | |
| | | | | _____ | |
| BANK BRANCH SERIAL NO. | | SCSB SERIAL NO. | | 3. BIDDER'S DEPOSITORY ACCOUNT DETAILS <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL | |
| | | | | _____ | |
| For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID | | | | | |

PLEASE CHANGE MY BID

| 4. FROM (AS PER LAST BID OR REVISION) | | | | | | | | | | | | | | | | | | | |
|--|---|---|---|---|---|---|---|---|--|---|---|-----------------|---|---|-----------|---|---|-----------------|--|
| Bid Options | No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 16000 Equity Shares) | | | | | | | | Price per Equity Share (₹) / (Price in multiples of ₹ 1/- only) (In Figures Only) | | | | | | | | | | |
| | (In Figures) | | | | | | | | Bid Price | | | Retail Discount | | | Net Price | | | (Please ✓ tick) | |
| | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 | 3 | 2 | 1 | 3 | 2 | 1 | 3 | 2 | 1 | | |
| Option 1 | | | | | | | | | | | | | | | | | | | |
| (OR) Option 2 | | | | | | | | | | | | | | | | | | | |
| (OR) Option 3 | | | | | | | | | | | | | | | | | | | |
| 5. TO (REVISED BID) (ONLY INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF") | | | | | | | | | | | | | | | | | | | |
| Bid Options | No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 16000 Equity Shares) | | | | | | | | Price per Equity Share (₹) / (Price in multiples of ₹ 1/- only) (In Figures Only) | | | | | | | | | | |
| | (In Figures) | | | | | | | | Bid Price | | | Retail Discount | | | Net Price | | | (Please ✓ tick) | |
| | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 | 3 | 2 | 1 | 3 | 2 | 1 | 3 | 2 | 1 | | |
| Option 1 | | | | | | | | | | | | | | | | | | | |
| (OR) Option 2 | | | | | | | | | | | | | | | | | | | |
| (OR) Option 3 | | | | | | | | | | | | | | | | | | | |

Please note that applications must be made in minimum of 3200 Equity Shares and further multiples of 1600 Equity Shares accordingly.

| 6. PAYMENT DETAILS [IN CAPITAL LETTERS] | | | | | | | | | | PAYMENT OPTION : FULL PAYMENT <input checked="" type="checkbox"/> | | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| Amount Blocked (₹ in figures) _____ | | | | | | | | | | (₹ in words) _____ | | | | | | | | | |
| ASBA Bank A/c No. _____ | | | | | | | | | | | | | | | | | | | |
| Bank Name & Branch _____ | | | | | | | | | | | | | | | | | | | |
| OR UPI ID (Maximum 45 characters) _____ | | | | | | | | | | | | | | | | | | | |
| I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUES ("GID") AND HEREBY AGREE AND CONFIRM THE 'BIDDER'S UNDERTAKING' AS GIVEN ALONG WITH THE BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM GIVEN OVERLEAF. | | | | | | | | | | | | | | | | | | | |
| 7A. SIGNATURE OF SOLE/ FIRST BIDDER | | | | | | | | | | 7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS) | | | | | | | | | |
| Date : _____, 2025 | | | | | | | | | | I/We authorise the SCSB to do all acts as are necessary to make the application in the Issue. | | | | | | | | | |
| | | | | | | | | | | 1) _____ | | | | | | | | | |
| | | | | | | | | | | 2) _____ | | | | | | | | | |
| | | | | | | | | | | 3) _____ | | | | | | | | | |
| | | | | | | | | | | MEMBERS OF THE SYNDICATE / SUB - SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system) | | | | | | | | | |

TEAR HERE

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|-----------------------------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|---|--|--|--|--|--|--|--|--|--|
| PC Diagnostics™ | | | | | | | | | | INVICTA DIAGNOSTIC LIMITED | | | | | | | | | | Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent | | | | | | | | | | Bid cum Application Form No. | | | | | | | | | |
| BID REVISION FORM - INITIAL PUBLIC OFFER - NR | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| DP ID / CL ID _____ | | | | | | | | | | PAN of Sole / First Bidder _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Additional Amount Blocked (₹ in figures) _____ | | | | | | | | | | ASBA Bank A/c No./UPI ID _____ | | | | | | | | | | Stamp & Signature of SCSB Branch | | | | | | | | | | | | | | | | | | | |
| Bank Name & Branch _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Received from Mr./Ms./M/s. _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Telephone / Mobile _____ | | | | | | | | | | Email _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

TEAR HERE

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| PC Diagnostics™ | | | | | | | | | | INVICTA DIAGNOSTIC LIMITED - BID REVISION FORM - INITIAL PUBLIC OFFER - NR | | | | | | | | | | Acknowledgement Slip for Bidder | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| DP ID / CL ID _____ | | | | | | | | | | PAN of Sole / First Bidder _____ | | | | | | | | | | | | | | | | | | | |
| Additional Amount Blocked (₹ in figures) _____ | | | | | | | | | | Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent | | | | | | | | | | Name of Sole / First Bidder _____ | | | | | | | | | |
| ASBA Bank A/c No. /UPI ID _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Bank Name & Branch _____ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |